Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Beleave Inc BLEVF

Beleave Inc is a vertically integrated Canadian cannabis company. It operates streamlined facilities throughout Canada to cultivate high quality cannabis flower, oil and extracts with funded capacity more than 150,000 kilograms per year. Fully licensed to cultivate and sell medical and recreational cannabis, it is leading the way through research partnerships with universities to bridge the gap between science and tradition and to develop pharma-grade extracts and derivatives. The company is currently developing new product lines as the recreational market is expected to allow for food and beverage-based cannabis products.


GREY:BLEVF - Post by User

Bullboard Posts
Post by PChung888on May 01, 2018 10:53am
198 Views
Post# 27964172

Acquiring Medi-Green

Acquiring Medi-Green
oronto, ON – May 1, 2018 – Beleave Inc. ("Beleave" or the "Company") (CSE: BE; OTCQX: BLEVF) is pleased to announce that it has entered into a definitive agreement to purchase all of the outstanding shares of 9334416 Canada Inc., o/a Medi-Green, Karmacann, and My-Grow ("Medi-Green"), a leading network of medical cannabis clinics with three current locations across Ontario (the "Transaction"). Subject to customary closing conditions, including the completion of certain filings with the Canadian Securities Exchange (the "CSE"), the Transaction is expected to close on or about May 8, 2018 (the "Closing Date").

Under the terms of the Transaction, Beleave will pay an aggregate purchase price of $3 million to the Medi-Green shareholders payable through the issuance of common shares in the capital of the Company (the "Beleave Shares") with price determined based on the Company’s 10-day VWAP leading up to closing.   The Medi-Green shareholders will also be entitled to receive up to $2 million of additional Beleave Shares if certain operational milestones are attained following the first twelve months of the Closing Date. 

“The acquisition of Medi-Green marks the first step in executing the Company’s client acquisition strategy while becoming more closely involved in an integral part of the patient experience.   Integrating with clinics is a proven model which provides a significant and fluid referral program between medical practitioners and prescribing doctors,” commented Andrew Wnek, Beleave’s Chief Executive Officer. “The Company plans to expand the reach of Medi-Green’s clinic network across Canada.”
 
Medi-Green has operated since 2015 and since then has opened 3 locations with plans to rapidly expand its footprint over the next 12 months.  The company currently has an active patient base of approximately 4,000 with average patient subscriptions in the 2 to 3 gram per day range.  Medi-Green has no long-term debt and had annual revenue of approximately $2.9 Million in 2017.  As part of the agreement the Medi-Green leadership team will remain on board and will continue operating the business as a wholly-owned subsidiary of Beleave. 
 
“Our team is eager and excited to work under the Beleave brand.  We feel our team aligns nicely with Beleave and their attention to quality assurance and sound science will be beneficial to our patients,” commented Trevor Hands, C.E.O. of Medi-Green. “Together I think we can bring strong vision and expertise to multiple areas of the ACMPR market, the newly emerging recreational sector, as well as other domestic and international opportunities.  We plan on adding at least six more locations by the end of 2018.”
 
About Beleave
Beleave Inc. is a biotech company and Beleave's wholly-owned subsidiary Beleave Kannabis Corp. (formerly First Access Medical Inc.) is a licensed producer pursuant to the ACMPR. Beleave's purpose-built facility is located in Hamilton, Ontario.

For further information please contact:
Sebastian de Kloet
Phone: (905) 979 - 5173      
Email: sebastian@beleave.com
beleave.com
Bullboard Posts